IBRX · available-data snapshot
ImmunityBio, Inc. (IBRX): Available-Data Snapshot
TickerWorth does not publish a DCF fair value for ImmunityBio, Inc. (IBRX); the reason is set out below. What its filings and market data do show is below. The snapshot also sets out its trading multiples against 5 peers. Snapshot as of Oct 19, 2026.
Model by Miraaj Patel · generated from public market data · Updated Oct 19, 2026 · How these pages are made
Why is there no fair value for IBRX?
We do not publish a fair value for ImmunityBio, Inc.. What we can say from its filings and market data is below.
What is IBRX's TickerWorth Score?
Priced richly vs peers — the business scores well
Compared with Healthcare companies in US
Its strongest point: growing quickly. Its weakest: looks expensive on the numbers.
- Value · 9 of 100
Cheaper than 9% of Healthcare companies in US
- Price vs worth · 0 of 100
- Quality · 55 of 100
More profitable than 55% of Healthcare companies in US
- Financial health · 56 of 100
Financially stronger than 56% of Healthcare companies in US
- Growth · 95 of 100
Growing faster than 95% of Healthcare companies in US
- Momentum · 81 of 100
Outperformed 81% of Healthcare companies in US over the past year
Confidence: Medium confidence · Scored
Get the Undervalued Company of the Week.
- Price
- $8.61
- Market cap
- $9,
119, 890, 432 - 52-week high
- $12.43
- 52-week low
- $1.95
- Currency
- USD
- Exchange
- NasdaqGS
Snapshot of Oct 19, 2026, quote time not published · Prices are delayed.
What we can say
We don't publish a discounted-cash-flow fair value for ImmunityBio, Inc. (IBRX) because the free data sources we rely on don't expose the multi-year financials a DCF needs — common for small or thinly-covered listings. Rather than invent numbers, this page shows an honest snapshot of what the public data does support: the current price and size, any relative valuation multiples that exist, a book-value view, and a price-based read. Treat it as a descriptive starting point, not a valuation and not investment advice.
Read the full reasoning
On the numbers we do have, IBRX trades at a recent price of $8.61, a market capitalisation of about $9,119,890,432, sitting 64% of the way up its 52-week range ($1.95–$12.43), on the NasdaqGS.
The standard alternative to a DCF is relative valuation — comparing IBRX's trading multiples against a sector benchmark. Here that gives P/S of 55.0× (richer than the peer median of 6.2×). A cheaper multiple than peers can flag a discount or a market that expects weaker growth; it is a comparison, not a recommendation.
Finally, a price-based read — explicitly not a valuation. IBRX is in an up-trend (price above both its 50- and 200-day averages), trading -30.8% from its 52-week high. Over the past year the stock is +274.7%. Moving-average trend and 52-week position describe where the stock has traded; they say nothing about what it is worth.
IBRX vs peers
Sector benchmark (bellwethers, not direct competitors).
| Multiple | IBRX | Peer median | Read |
|---|---|---|---|
| P/S | 55.0× | 6.2× | richer than |
What does ImmunityBio, Inc. do?
What does it do?
ImmunityBio, Inc., a biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient's immune system and deliver durable protection against cancer and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies. It operates in the Biotechnology industry (Healthcare sector), headquartered in United States. The company employs roughly 684 people.
How does it make money?
The business turns $166M in annual revenue into profit. Out of every $100 of sales, about $0 is left as operating profit (operating margin of -120.4%), after a 99% gross margin on the products/services it sells. After all costs, taxes and interest, 0.0% of revenue becomes bottom-line net profit.
Is it financially healthy?
Financially it looks mixed: comfortably covers its short-term bills (5.7× current ratio), and is currently lossmaking.
Who at IBRX filed insider trades?
| Date | Insider | Relationship | What happened | Value | Filing |
|---|---|---|---|---|---|
| Simon Barry J. | Director | Open-market sale | $268,760.00 | Form 4 for Simon Barry J. (opens sec.gov in a new tab) | |
| Cohen Cheryl | Director | Option exercise | $166,817.42 | Form 4 for Cohen Cheryl (opens sec.gov in a new tab) | |
| Cohen Cheryl | Director | Open-market sale | $851,088.00 | Form 4 for Cohen Cheryl (opens sec.gov in a new tab) | |
| Cohen Cheryl | Director | Option exercise | $166,817.42 | Form 4 for Cohen Cheryl (opens sec.gov in a new tab) | |
| Cohen Cheryl | Director | Open-market sale | $1,246,941.11 | Form 4 for Cohen Cheryl (opens sec.gov in a new tab) | |
| Selecky Christobel | Director | Option exercise | $104,490.72 | Form 4 for Selecky Christobel (opens sec.gov in a new tab) |
A disclosure, not a signal to trade. Source: SEC EDGAR (Form 4). Older filings and the 90-day buying-and-selling read are part of Pro. See plans
Companies we do put a number on
Not investment advice. TickerWorth Score is a model output.
A descriptive, available-data snapshot and relative comparison — NOT a DCF, NOT a price target, and NOT investment advice. TickerWorth is not a licensed investment adviser, and these figures are estimates from public market data that can be wrong, stale or incomplete.